Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study
PLOS Medicine · 2023
DOI: 10.1371/journal.pmed.1004086 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS Medicine, 2023. Verfasst von Lance Turtle und 19 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Department of Clinical Infection, Microbiology and Immunology, Institute of…. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Department of Health.
Abstract (Originalsprache)
Background
Immunocompromised patients may be at higher risk of mortality if hospitalised with Coronavirus Disease 2019 (COVID-19) compared with immunocompetent patients. However, previous studies have been contradictory. We aimed to determine whether immunocompromised patients were at greater risk of in-hospital death and how this risk changed over the pandemic. Methods and findings We included patients > = 19 years with symptomatic community-acquired COVID-19 recruited to the ISARIC WHO Clinical Characterisation Protocol UK prospective cohort study. We defined immunocompromise as immunosuppressant medication preadmission, cancer treatment, organ transplant, HIV, or congenital immunodeficiency. We used logistic regression to compare the risk of death in both groups, adjusting for age, sex, deprivation, ethnicity, vaccination, and comorbidities. We used Bayesian logistic regression to explore mortality over time. Between 17 January 2020 and 28 February 2022, we recruited 156,552 eligible patients, of whom 21,954 (14%) were immunocompromised. In total, 29% ( n = 6,499) of immunocompromised and 21% ( n = 28,608) of immunocompetent patients died in hospital. The odds of in-hospital mortality were elevated for immunocompromised patients (adjusted OR 1.44, 95% CI [1.39, 1.50], p < 0.001). Not all immunocompromising conditions had the same risk, for example, patients on active cancer treatment were less likely to have their care escalated to intensive care (adjusted OR 0.77, 95% CI [0.7, 0.85], p < 0.001) or ventilation (adjusted OR 0.65, 95% CI [0.56, 0.76], p < 0.001). However, cancer patients were more likely to die (adjusted OR 2.0, 95% CI [1.87, 2.15], p < 0.001). Analyses were adjusted for age, sex, socioeconomic deprivation, comorbidities, and vaccination status. As the pandemic progressed, in-hospital mortality reduced more slowly for immunocompromised patients than for immunocompetent patients. This was particularly evident with increasing age: the probability of the reduction in hospital mortality being less for immunocompromised patients aged 50 to 69 years was 88% for men and 83% for women, and for those >80 years was 99% for men and 98% for women. The study is limited by a lack of detailed drug data prior to admission, including steroid doses, meaning that we may have incorrectly categorised some immunocompromised patients as immunocompetent.
Conclusions
Immunocompromised patients remain at elevated risk of death from COVID-19. Targeted measures such as additional vaccine doses, monoclonal antibodies, and nonpharmaceutical preventive interventions should be continually encouraged for this patient group.
Trial registration
ISRCTN 66726260 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Department of Clinical Infection, Microbiology and Immunology, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpoo…
- Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.
- Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
- Department of Infectious Diseases, Leiden University Medical Centre, Leiden University, Leiden, the Netherlands.
- The Roslin Institute, Easter Bush campus, University of Edinburgh, Edinburgh, United Kingdom.
- Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
ORCID-Profile: Lance Turtle, Mathew Thorpe, Maaike Swets, Stephen Aston, Thushan I de Silva, Peter J M Openshaw, J Kenneth Baillie, Malcolm G Semple, Annemarie B Docherty
Förderung
- Wellcome Trust
- Medical Research Council
- Department of Health
- NIHR
- Chief Scientist Office, Scottish Government Health and Social Care Directorate
- Bill and Melinda Gates Foundation
- Liverpool Experimental Cancer Medicine Centre
- PREPARE
Zitieren
APA
Turtle, L., Thorpe, M., Drake, T. M., Swets, M., Palmieri, C., Russell, C. D., Ho, A., Aston, S., Wootton, D. G., Richter, A., de Silva, T. I., Hardwick, H. E., Leeming, G., Law, A., Openshaw, P. J. M., Harrison, E. M., ISARIC4C investigators, Baillie, J. K., Semple, M. G., & Docherty, A. B. (2023). Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1004086
Vancouver
Turtle L, Thorpe M, Drake TM, Swets M, Palmieri C, Russell CD, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study. PLOS Medicine. 2023. doi:10.1371/journal.pmed.1004086
BibTeX
@article{Turtle2023,
author = {Turtle, Lance and Thorpe, Mathew and Drake, Thomas M and Swets, Maaike and Palmieri, Carlo and Russell, Clark D and Ho, Antonia and Aston, Stephen and Wootton, Daniel G and Richter, Alex and de Silva, Thushan I and Hardwick, Hayley E and Leeming, Gary and Law, Andy and Openshaw, Peter J M and Harrison, Ewen M and ISARIC4C investigators, ISARIC4C investigators and Baillie, J Kenneth and Semple, Malcolm G and Docherty, Annemarie B},
title = {Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study},
journal = {PLOS Medicine},
year = {2023},
doi = {10.1371/journal.pmed.1004086}
}
EUVIMED